Have you seen this week's Daily Minutes? Click here and go to the green box to see short clips discussing:
- Allowing axons to grow
- Explaining bladder dysfunction
May 07, 2009
Proposals sought from academic institutions and seed-to-early stage companies developing novel therapeutic approaches to prevent, treat or reverse nervous system damage in multiple sclerosis
Fast Forward, LLC, a wholly-owned subsidiary of the National MS Society, and EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a commitment of $3 million in 2009 to support innovative early-stage projects directed towards the development of therapies to prevent treat, or reverse nervous system damage in MS. This is the first "Request for Proposals" (RFP) issued under the auspices of a multi-year collaboration between Fast Forward and EMD Serono to accelerate innovation and commercial development of MS therapies. Merck KGaA, the parent corporation of EMD Serono, Inc., will provide up to $19 million in total funding for the collaboration.
To read complete article please click this link that will re-direct you to the National MS Society website's article.
If not yet registered to receive the "Stu's Views and MS Related News", weekly MS related e-newsletter, then please Click Here to register.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
Every hour in the United States, someone is diagnosed with multiple sclerosis, an unpredictable, often disabling disease of the central nervous system. While it’s the most common neurological condition affecting young to middle-aged adults, emerging research suggests up to 10,000 children in the U.S. are living with the condition and another 15,000 have experienced MS-like symptoms such as double vision, numbness and unexplained fatigue.
On May 27th, MS in BalanceSM will release a new online video:
In just 30 minutes, you can get important facts about MRI—including how doctors may use them to help manage your relapsing MS.
This Talk MS program will feature special guests, including:
|Randall Schapiro, MD|
|MS LifeLines® Ambassador Catherine|
“I am pleased that we were able to work quickly to address the comments from the
Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. Fampridine-SR is being developed by
New Strategy Captures Drug Maker's Interest
EMD Serono, Inc., agreed to provide Fast Forward, LLC, the Society's drug discovery subsidiary, with up to $19 million for early stage clinical development projects.
Please return to this page to leave any comments you may have
This venture takes you thru a rolling-stroll of his in Central Park, where fortunately ( on this day of taping) there weren't many hardships for navigating in a wheelchair...
More of his ventures will soon be coming and as he releases each one, you will find it on this blog...
Have you seen who (or what) MS Organization he shows at the end of each of his videos?
Check out his site (click the link found above) to learn more...